Effects of Nevirapine on the Steady State Pharmacokinetics of Fluconazole in HIV Positive Patients

Boehringer Ingelheim

Status and phase

Completed

Phase 4

Conditions

HIV Infections

Treatments

Drug: Fluconazole

Drug: Nevirapine

Study type

Interventional

Funder types

Industry

Identifiers

NCT02181946

1100.1361

Details and patient eligibility

About

The purpose of this study was to determine the effects of nevirapine on the steady state pharmacokinetics of fluconazole and to assess the steady-state pharmacokinetics of nevirapine when given in combination with fluconazole.

Enrollment

24 patients

Sex

All

Ages

18 to 65 years old

Volunteers

No Healthy Volunteers

Inclusion criteria

Male or female patients between the ages of 18 and 65 years who are seropositive for HIV-1 antibody by an ELISA test and confirmed by an alternative method, e.g. Western Blot
CD4 + cell count ≥ 100 cells/mm3
Patients who meet the following laboratory parameters
- Granulocyte count > 1000 cells/mm3
- Hemoglobin > 9.0 g/dl (men and women)
- Platelet count > 75,000 cells/mm3
- Alkaline phosphatase < 3.0 times the upper limit of normal
- Aspartame Transaminase (AST) and Alanine Transaminase (ALT) < 3.0 times the upper limit of normal
- Total bilirubin < 1.5 times the upper limit of normal
Female patients of childbearing potential must be willing to use a reliable form of contraception which must include a medically approved from of barrier contraception
Patients able to provide written informed consent and comply with study requirements

Exclusion criteria

Female patients who are pregnant or breast-feeding
Seated systolic blood pressure below 100 mmHg, or greater than 160 mmHg, and/or heart rate less than 50 or greater than 100 beats/min
History of drug allergy or known drug hypersensitivity
Patients receiving any investigational drug, antineoplastic agent or radiotherapy other than local skin radiotherapy treatment within 12 weeks before starting study medication
Patients requiring systemic treatment with corticosteroids or drugs known to be hepatic enzyme inducers or inhibitors within 28 days of study entry (Study Day 1). Such substances in these categories include: macrolide antibiotics (e.g. erythromycin, clarithromycin, azithromycin, dirithromycin), azole antifungals (e.g. itraconazole), rifabutin and phenytoin
Patients requiring systemic treatment with CYP3A4 (cytochrome P450 3A4) substrates such as terfenadine, astemizole, cisapride, triazolam and midazolam during the course of the trial
Use of protease inhibitors or non-nucleoside reverse transcriptase inhibitors within 28 days of Study Day 1 or during the trial
Patients with a current history of intravenous drug abuse, alcohol or substance abuse (within the last year)
History of any clinically important disease including hepatic, renal, cardiovascular or gastrointestinal disease
Patients with malabsorption, severe chronic diarrhea or patients unable to maintain adequate oral intake